Version 1
: Received: 16 October 2024 / Approved: 17 October 2024 / Online: 17 October 2024 (17:06:18 CEST)
How to cite:
Valdez, T.; Patel, V.; Senesombath, D.; Hatahet-Donovan, Z.; Hornick, M. G. Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders. Preprints2024, 2024101406. https://doi.org/10.20944/preprints202410.1406.v1
Valdez, T.; Patel, V.; Senesombath, D.; Hatahet-Donovan, Z.; Hornick, M. G. Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders. Preprints 2024, 2024101406. https://doi.org/10.20944/preprints202410.1406.v1
Valdez, T.; Patel, V.; Senesombath, D.; Hatahet-Donovan, Z.; Hornick, M. G. Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders. Preprints2024, 2024101406. https://doi.org/10.20944/preprints202410.1406.v1
APA Style
Valdez, T., Patel, V., Senesombath, D., Hatahet-Donovan, Z., & Hornick, M. G. (2024). Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders. Preprints. https://doi.org/10.20944/preprints202410.1406.v1
Chicago/Turabian Style
Valdez, T., Zayd Hatahet-Donovan and Mary Grace Hornick. 2024 "Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders" Preprints. https://doi.org/10.20944/preprints202410.1406.v1
Abstract
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have historically hindered further research into this area. Nevertheless, concurrent with the rise in SUDs and other mental health conditions, researchers have again turned their attention to these compounds, searching for differing pharmacological targets as well as more holistic treatments that might increase patient adherence and efficacy. The aim of this review is to examine the emerging evidence with regards to the therapeutic treatment of SUDs with the psychedelic compounds psilocybin, ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ayahuasca, ibogaine and peyote.
Medicine and Pharmacology, Psychiatry and Mental Health
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
